Concepedia

Publication | Closed Access

Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily

DOI

105

Citations

21

References

2009

Year

Christian Sillaber, Harald Herrmann, Keiryn L. Bennett, Uwe Rix, Christian Baumgärtner, Alexandra Böhm, Susanne Herndlhofer, Erwin Tschachler, Giulio Superti‐Furga, Ulrich Jäger,
European Journal of Clinical Investigation

Abstract

Dasatinib acts not only anti-neoplastic in CML but may also act as an immunosuppressive agent when applied at 140 mg daily, and produces frequent pleural effusions and weight loss in advanced CML.

References

YearCitations

Page 1